What Is The Current and Historic Market Size Analysis Of The Acquired Hemophilia Treatment Market?
The acquired hemophilia treatment market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a robust growth in the market size of acquired hemophilia treatment. It's expected to expand from $12.2 billion in 2024 to $12.96 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%.
Factors driving the growth during the historic period include a growing aging population, enhancements in diagnostic procedures and awareness, an increase in the patient pool, collaborative research initiatives, and regulatory support and approval.
What Is The Forecast For The Acquired Hemophilia Treatment Market Size Evolve over the Forecast Period?
The acquired hemophilia treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for treating acquired hemophilia is predicted to exhibit balanced growth in the near future. It's projected to expand to $15.56 billion by 2029, showcasing a Compound Annual Growth Rate (CAGR) of 4.7%.
The anticipated growth during the forecast timeframe is linked to factors such as the increasing global population, augmented investments in healthcare, trend toward personalized medicine, global partnerships in research, enhanced health consciousness, and regulatory backing for orphan drugs. Dominant trends expected during this period encompass improved monitoring and diagnostic technologies, alliance for patient assistance programs, research into gene therapy methods, escalated use of immune tolerance initiation, and the application of telemedicine for distant consultations.
What Factors Are Driving Growth In The Acquired Hemophilia Treatment Market?
The projected escalation in ongoing clinical trials is anticipated to boost the acquired hemophilia treatment market's advancement. Clinical trials, which are research investigations involving human subjects to assess the safety and efficiency of innovative medical solutions, treatments, or diagnostic methods, are decisive for the growth. They aim to evaluate the safety and performance of new treatments for acquired hemophilia, propelling research to enhance patient outcomes and create effective curative interventions. As an illustration, according to ClinicalTrials.gov, a division of the National Institutes of Health (NIH), a U.S. governmental institution accountable for managing and promoting medical research, stated that the number of studies registered escalated from 437,523 in 2022 to 468,457 in all the U.S. states and 221 international countries in October 2023. It was additionally reported that out of the total, 143,613 studies (representing 31%) are registered in the U.S, and 251,159 studies (amounting to 54%) are registered outside of the U.S. Therefore, the escalating number of continuous clinical trials is pushing the growth in the acquired hemophilia treatment market. Acquired Hemophilia Treatment Market Driver: Escalating Healthcare Spending Fuels Advancement In The Acquired Hemophilia Treatment Market
How Is The Global Acquired Hemophilia Treatment Market Divided Into Key Segments?
The acquired hemophilia treatment market covered in this report is segmented –
1) By Treatment: On-Demand, Prophylaxis
2) By Type: Hemophilia A, Hemophilia B, Hemophilia C, Other Types
3) By End User: Hospitals, Clinic, Other End Users
Subsegments:
1) By On-Demand: Clotting Factor Replacement Therapy, Desmopressin, Other On-Demand Treatments
2) By Prophylaxis: Clotting Factor Replacement Therapy, Gene Therapy, Other Prophylaxis Treatments
Pre-Book The Acquired Hemophilia Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Acquired Hemophilia Treatment Market?
Major players in the acquired hemophilia treatment marketplace are focusing on supplementing their medicinal offerings and securing approval to maintain market positioning. The number of drugs being approved for regular preventive treatment is on the rise, predominantly due to the need for safer and more potent alternatives. For instance, in June 2022, Japan's Chugai Pharmaceutical received extended approval from the country's Ministry of Health, Labor and Welfare, expanding the utilization of Hemlibra (emicizumab) for regular preventive measures designed to decrease or prevent bleeding incidents in individuals diagnosed with acquired hemophilia A. Following this authorization, additional steps to quickly monitor and manage bleeding right after diagnosis were approved, using Hemlibra, a bispecific antibody, which simultaneously binds to the factor IX and factor X binding locations involved in blood clotting.
Who Are the Key Players In The Acquired Hemophilia Treatment Market?
Major companies operating in the acquired hemophilia treatment market report are:
• Pfizer Inc.
• Roche Holding AG
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Sanofi SA
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Novo Nordisk A/S
• Baxter Healthcare Corporation
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Biogen Inc.
• CSL Limited
• Grifols SA
• Genentech Inc.
• Octapharma AG
• Ferring Pharmaceuticals BV
• Shire PLC
• BioMarin Pharmaceutical Inc.
• Sobi Inc.
• Kedrion Biopharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Spark Therapeutics Inc.
• Medexus Pharmaceuticals Inc.
• UniQure NV
• Catalyst Biosciences Inc.
• Hema Biologics LLC
• BioXcel Corporation
What Are The Regional Insights Into The Acquired Hemophilia Treatment Market?
North America was the largest region in the acquired hemophilia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
